{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:41:02Z","timestamp":1791207662099,"version":"4.1.0"},"reference-count":229,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.pharmthera.2012.07.007","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T02:03:45Z","timestamp":1342749825000},"page":"227-266","source":"Crossref","is-referenced-by-count":136,"title":["Pharmaceutical therapies to recode nonsense mutations in inherited diseases"],"prefix":"10.1016","volume":"136","author":[{"given":"Hui-Ling Rose","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.07.007_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2006.11.046","article-title":"tRNA's wobble decoding of the genome: 40 years of modification","volume":"366","author":"Agris","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/hmg\/9.17.2507","article-title":"Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy","volume":"9","author":"Ahmad","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jgm.1140","article-title":"Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes","volume":"10","author":"Allamand","year":"2008","journal-title":"J Gene Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0020","doi-asserted-by":"crossref","first-page":"13191","DOI":"10.1016\/S0021-9258(18)42193-X","article-title":"Partial phenotypic suppression of a peroxisome-deficient animal cell mutant treated with aminoglycoside G418","volume":"267","author":"Allen","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03060","article-title":"A faux 3\u2032-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay","volume":"432","author":"Amrani","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0035","first-page":"313","article-title":"Negamycin-therapy in skeletal and cardiac muscles of mdx Mice","volume":"13","author":"Arakawa","year":"2003","journal-title":"Basic Appl Myol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jb\/mvg203","article-title":"Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice","volume":"134","author":"Arakawa","year":"2003","journal-title":"J Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS statement: Guidelines for the six-minute walk test","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0050","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1073\/pnas.0909141107","article-title":"Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124","volume":"107","author":"Auld","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0055","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ppul.10110","article-title":"Spinal muscular atrophy type 1: Management and outcomes","volume":"34","author":"Bach","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0167-4781(83)90018-0","article-title":"G-418, an elongation inhibitor of 80 S ribosomes","volume":"741","author":"Bar-Nun","year":"1983","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0075","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1073\/pnas.111145698","article-title":"Spatial and temporal control of RNA stability","volume":"98","author":"Bashirullah","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0080","first-page":"858","article-title":"Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid","volume":"255","author":"Beauchamp","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/978-3-642-71248-7_52","article-title":"Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats","volume":"9","author":"Beauchamp","year":"1986","journal-title":"Arch Toxicol Suppl"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0090","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0095","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/sj.emboj.7601588","article-title":"A conserved role for cytoplasmic poly(A)-binding protein 1 (PABPC1) in nonsense-mediated mRNA decay","volume":"26","author":"Behm-Ansmant","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0100","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1046\/j.1432-1033.2003.03694.x","article-title":"Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes","volume":"270","author":"Berens","year":"2003","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.gt.3302211","article-title":"Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment","volume":"11","author":"Bidou","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/jmbi.1995.0438","article-title":"The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae","volume":"251","author":"Bonetti","year":"1995","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.nmd.2007.06.080","article-title":"G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD) [abstract]","volume":"17","author":"Bonnemann","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00109-010-0704-4","article-title":"Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model","volume":"89","author":"Brendel","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1203\/PDR.0b013e31819d9ebc","article-title":"Suppression of nonsense mutations in Rett syndrome by aminoglycoside antibiotics","volume":"65","author":"Brendel","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0130","series-title":"Hemophilia A","author":"Brower","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0135","series-title":"Hemophilia B","author":"Brower","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0140","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1093\/nar\/18.21.6339","article-title":"Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes","volume":"18","author":"Brown","year":"1990","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.007_bb0145","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/oby.2011.202","article-title":"Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through","volume":"20","author":"Brumm","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ymgme.2009.04.004","article-title":"Stop codon read-through of a methylmalonic aciduria mutation","volume":"97","author":"Buck","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0155","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0160","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-2-3","article-title":"UAG readthrough in mammalian cells: Effect of upstream and downstream stop codon contexts reveal different signals","volume":"2","author":"Cassan","year":"2001","journal-title":"BMC Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0170","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1093\/nar\/19.12.3185","article-title":"Eukaryotic start and stop translation sites","volume":"19","author":"Cavener","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0175","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/ol0269042","article-title":"Pyranmycins, a novel class of aminoglycosides with improved acid stability: The SAR of D-pyranoses on ring III of pyranmycin","volume":"4","author":"Chang","year":"2002","journal-title":"Org Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0180","series-title":"MECP2-related disorders","author":"Christodoulou","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0185","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0190","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0195","series-title":"Dystrophinopathies","author":"Darras","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0200","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/MMBR.51.3.341-350.1987","article-title":"Mechanism of bactericidal action of aminoglycosides","volume":"51","author":"Davis","year":"1987","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.20422","article-title":"Protein- and mRNA-based phenotype-genotype correlations in DMD\/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene","volume":"28","author":"Deburgrave","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajmg.a.30617","article-title":"Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort","volume":"134","author":"Dent","year":"2005","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1101\/gr.7.4.339","article-title":"Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene","volume":"7","author":"DiDonato","year":"1997","journal-title":"Genome Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.crvi.2006.09.001","article-title":"Aminoglycosides and other factors promoting stop codon readthrough in human cells","volume":"330","author":"Diop","year":"2007","journal-title":"C R Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0225","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/jcb.22979","article-title":"Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations","volume":"112","author":"Dranchak","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0235","article-title":"Preclinical pharmacology and toxicology of PTC124 as nonsense mutation suppression therapy for cystic fibrosis","volume":"38","author":"Du","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0230","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1084\/jem.20081940","article-title":"Nonaminoglycoside compounds induce readthrough of nonsense mutations","volume":"206","author":"Du","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0240","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr\u2212\/\u2212 mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0245","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1074\/jbc.M806728200","article-title":"Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model","volume":"284","author":"Du","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","article-title":"Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model","volume":"84","author":"Du","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0255","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0260","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1371\/journal.pbio.0060092","article-title":"Posttranscriptional gene regulation by spatial rearrangement of the 3\u2032 untranslated region","volume":"6","author":"Eberle","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0265","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/jo035290r","article-title":"Application of the synthetic aminosugars for glycodiversification: synthesis and antimicrobial studies of pyranmycin","volume":"69","author":"Elchert","year":"2004","journal-title":"J Org Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2014A world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0275","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0285","doi-asserted-by":"crossref","first-page":"8860","DOI":"10.1073\/pnas.87.22.8860","article-title":"Identification of amino acids inserted during suppression of UAA and UGA termination codons at the gag-pol junction of Moloney murine leukemia virus","volume":"87","author":"Feng","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0290","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/374176","article-title":"Rapid direct sequence analysis of the dystrophin gene","volume":"72","author":"Flanigan","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.007_bb0295","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1093\/nar\/gkq1277","article-title":"Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides","volume":"39","author":"Floquet","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cmdc.200500029","article-title":"In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa","volume":"1","author":"Fortin","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0305","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0310","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/FPC.0b013e328349daba","article-title":"Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon","volume":"21","author":"Fuchshuber-Moraes","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0315","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.braindev.2004.06.003","article-title":"Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: Pathological mutations and polymorphisms","volume":"27","author":"Fukuda","year":"2005","journal-title":"Brain Dev"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0320","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/hmg\/ddn162","article-title":"RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology","volume":"17","author":"Ghahramani Seno","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0325","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/159.5.945","article-title":"Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity","volume":"159","author":"Gilbert","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0330","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.2010.067","article-title":"PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C","volume":"22","author":"Goldmann","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0335","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1167\/iovs.10-5741","article-title":"Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina","volume":"51","author":"Goldmann","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0340","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0345","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V83.8.2031.2031","article-title":"Nonsense codon mutations in the terminal exon of the beta-globin gene are not associated with a reduction in beta-mRNA accumulation: A mechanism for the phenotype of dominant beta-thalassemia","volume":"83","author":"Hall","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0350","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7164\/antibiotics.23.170","article-title":"A new antibiotic, negamycin","volume":"23","author":"Hamada","year":"1970","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0355","first-page":"783","article-title":"Drug evaluation: PTC-124\u2014A potential treatment of cystic fibrosis and Duchenne muscular dystrophy","volume":"9","author":"Hamed","year":"2006","journal-title":"IDrugs"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0360","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2010.10.033","article-title":"RNA polymerase II subunits link transcription and mRNA decay to translation","volume":"143","author":"Harel-Sharvit","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0365","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/nar\/30.9.2011","article-title":"Predominance of six different hexanucleotide recoding signals 3\u2032 of read-through stop codons","volume":"30","author":"Harrell","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2012.07.007_bb0370","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2516.2007.01574.x","article-title":"Inhibitors in haemophilia A: Current management and open issues","volume":"13","author":"Haya","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0375","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo","volume":"18","author":"Heier","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0380","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/0883073807305669","article-title":"SMN transcript stability: Could modulation of messenger RNA degradation provide a novel therapy for spinal muscular atrophy?","volume":"22","author":"Heier","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0385","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","article-title":"alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients","volume":"338","author":"Hein","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jmg.2009.066969","article-title":"Differences in SMN1 allele frequencies among ethnic groups within North America","volume":"46","author":"Hendrickson","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0405","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ana.20052","article-title":"Readthrough of dystrophin stop codon mutations induced by aminoglycosides","volume":"55","author":"Howard","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0400","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0410","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B","article-title":"Sequence specificity of aminoglycoside-induced stop codon readthrough: Potential implications for treatment of Duchenne muscular dystrophy","volume":"48","author":"Howard","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0415","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/08830738050200082101","article-title":"Molecular diagnosis of Rett syndrome","volume":"20","author":"Huppke","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0420","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0092-8674(01)00475-5","article-title":"Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20","volume":"106","author":"Ishigaki","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0425","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/emboj.2008.17","article-title":"Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways","volume":"27","author":"Ivanov","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0430","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2005-03-1307","article-title":"Aminoglycoside suppression of nonsense mutations in severe hemophilia","volume":"106","author":"James","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0435","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/35067016","article-title":"mRNA localization: Message on the move","volume":"2","author":"Jansen","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0440","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/hmg\/ddn026","article-title":"Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice","volume":"17","author":"Jugloff","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0445","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.bmcl.2011.07.107","article-title":"Synthesis and evaluation of compounds that induce readthrough of premature termination codons","volume":"21","author":"Jung","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0450","unstructured":"Karp, G. M., Hwang, S., Chen, G., & Almstead, N. G. (2010). 1,2,4-Oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease. In USPTO (Ed.), (Vol. 7772259). US: PTC Therapeutics, Inc."},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0455","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.1389006","article-title":"Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay","volume":"20","author":"Kashima","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0460","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system","volume":"80","author":"Keeling","year":"2002","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0465","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0470","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: How much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0475","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0480","first-page":"424","article-title":"Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats","volume":"262","author":"Kishore","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0485","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0490","series-title":"Aminoglycoside antibiotics: From chemical biology to drug discovery","first-page":"209","article-title":"Structural comparisons between prokaryotic and eukaryotic ribosomal decoding a sites free and complexed with aminoglycosides","author":"Kondo","year":"2007"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0495","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1016\/S0040-4039(00)94251-5","article-title":"Clitocine, a new insecticidal nucleoside from the mushroom Clitocybe inversa","volume":"27","author":"Kubo","year":"1986","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0500","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.3","article-title":"Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions","volume":"17","author":"Laccone","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0510","doi-asserted-by":"crossref","first-page":"15676","DOI":"10.1073\/pnas.0405155101","article-title":"Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons","volume":"101","author":"Lai","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.47102\/annals-acadmedsg.V34N1p73","article-title":"SMN1 deletions among Singaporean patients with spinal muscular atrophy","volume":"34","author":"Lai","year":"2005","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0515","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1093\/emboj\/19.24.6860","article-title":"The spliceosome deposits multiple proteins 20\u201324 nucleotides upstream of mRNA exon-exon junctions","volume":"19","author":"Le Hir","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0520","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/mt.2011.90","article-title":"Post-transcriptionally regulated expression system in human xenogeneic transplantation models","volume":"19","author":"Lee","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0535","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/emboj\/cdf345","article-title":"The exon junction complex is detected on CBP80-bound but not eIF4E-bound mRNA in mammalian cells: dynamics of mRNP remodeling","volume":"21","author":"Lejeune","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0540","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/humu.20104","article-title":"Mutations in the MMAA gene in patients with the cblA disorder of vitamin B12 metabolism","volume":"24","author":"Lerner-Ellis","year":"2004","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0545","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1073\/pnas.0136770100","article-title":"Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans","volume":"100","author":"Lewis","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0550","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/ol0497685","article-title":"Application of glycodiversification: Expedient synthesis and antibacterial evaluation of a library of kanamycin B analogues","volume":"6","author":"Li","year":"2004","journal-title":"Org Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0555","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0560","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.biosystems.2005.05.005","article-title":"Comparative analysis of base biases around the stop codons in six eukaryotes","volume":"81","author":"Liu","year":"2005","journal-title":"Biosystems"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0565","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0570","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1093\/hmg\/ddq147","article-title":"Spinal muscular atrophy: Mechanisms and therapeutic strategies","volume":"19","author":"Lorson","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0575","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.ATV.0000118683.99628.42","article-title":"Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: Total recovery after a treatment with the aminoglycoside gentamicin","volume":"24","author":"Loufrani","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0580","series-title":"Methylmalonic acidemia","author":"Manoli","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0585","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0590","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1097-4644(19980801)70:2<181::AID-JCB4>3.0.CO;2-K","article-title":"Of coiled bodies, gems, and salmon","volume":"70","author":"Matera","year":"1998","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0595","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model","volume":"18","author":"Mattis","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0600","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00439-006-0245-7","article-title":"Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts","volume":"120","author":"Mattis","year":"2006","journal-title":"Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0605","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.92.12.5431","article-title":"Translational termination efficiency in mammals is influenced by the base following the stop codon","volume":"92","author":"McCaughan","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0610","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: Longitudinal observations","volume":"42","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0615","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(03)13368-5","article-title":"Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study","volume":"361","author":"McKone","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0620","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1212\/WNL.57.4.645","article-title":"Diagnosis of Duchenne dystrophy by enhanced detection of small mutations","volume":"57","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0625","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0092-8674(01)00583-9","article-title":"When the message goes awry: disease-producing mutations that influence mRNA content and performance","volume":"107","author":"Mendell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0630","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/ng1429","article-title":"Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise","volume":"36","author":"Mendell","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0635","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7164\/antibiotics.23.589","article-title":"Mechanism of action of negamycin in Escherichia coli K12. II. Miscoding activity in polypeptide synthesis directed by synthetic polynucleotide","volume":"23","author":"Mizuno","year":"1970","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0640","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0645","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(\u2212\/\u2212) mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0650","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1021\/jm00399a017","article-title":"Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside","volume":"31","author":"Moss","year":"1988","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0655","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/j.1460-2075.1994.tb06255.x","article-title":"The second to last amino acid in the nascent peptide as a codon context determinant","volume":"13","author":"Mottagui-Tabar","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0660","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-5793(97)00978-2","article-title":"Only the last amino acids in the nascent peptide influence translation termination in Escherichia coli genes","volume":"414","author":"Mottagui-Tabar","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0665","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1432-1327.1998.2570249.x","article-title":"The influence of 5\u2032 codon context on translation termination in Saccharomyces cerevisiae","volume":"257","author":"Mottagui-Tabar","year":"1998","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0670","unstructured":"Mulligan, R., & Murphy, G. J. (2009). Methods and compositions for regulating gene expression. In USPTO (Ed.), (Vol. 20090304641A1). US: Children's Hospital Boston (Boston, MA, US)."},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0675","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/nm1376","article-title":"Exogenous control of mammalian gene expression via modulation of translational termination","volume":"12","author":"Murphy","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0680","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/humu.21632","article-title":"Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia","volume":"33","author":"Nakamura","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0685","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/embo-reports\/kve176","article-title":"Impact of the six nucleotides downstream of the stop codon on translation termination","volume":"2","author":"Namy","year":"2001","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(03)00050-2","article-title":"Glutamine is incorporated at the nonsense codons UAG and UAA in a suppressor-free Escherichia coli strain","volume":"1627","author":"Nilsson","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0695","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations","volume":"18","author":"Nudelman","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0700","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations","volume":"52","author":"Nudelman","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0705","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.bmcl.2006.09.013","article-title":"Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations","volume":"16","author":"Nudelman","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0710","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1126\/science.1060612","article-title":"Recognition of cognate transfer RNA by the 30S ribosomal subunit","volume":"292","author":"Ogle","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0715","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0968-0004(03)00066-5","article-title":"Insights into the decoding mechanism from recent ribosome structures","volume":"28","author":"Ogle","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0720","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0092-8674(02)01086-3","article-title":"Selection of tRNA by the ribosome requires a transition from an open to a closed form","volume":"111","author":"Ogle","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0725","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.biochem.74.061903.155440","article-title":"Structural insights into translational fidelity","volume":"74","author":"Ogle","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0730","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S1097-2765(03)00443-X","article-title":"Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7","volume":"12","author":"Ohnishi","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0735","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0092-8674(78)90201-5","article-title":"Mistranslation in a eucaryotic organism","volume":"13","author":"Palmer","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0740","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/277148a0","article-title":"Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics","volume":"277","author":"Palmer","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0745","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1086\/302160","article-title":"Intragenic telSMN mutations: Frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number","volume":"63","author":"Parsons","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0750","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy","volume":"15","author":"Pearn","year":"1978","journal-title":"J Med Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0755","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1073\/pnas.0901936106","article-title":"Nonsense suppression activity of PTC124 (ataluren)","volume":"106","author":"Peltz","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0760","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/0883073807308715","article-title":"Rett syndrome: North American database","volume":"22","author":"Percy","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0765","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0770","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1128\/MCB.15.12.6593","article-title":"Context effects on misreading and suppression at UAG codons in human cells","volume":"15","author":"Phillips-Jones","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0775","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-09-3879","article-title":"Bleeding in carriers of hemophilia","volume":"108","author":"Plug","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0780","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/jnr.22409","article-title":"Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro","volume":"88","author":"Popescu","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0785","series-title":"Spinal muscular atrophy","author":"Prior","year":"1993"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0790","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.4065\/80.11.1485","article-title":"Hemophilia: A practical approach to genetic testing","volume":"80","author":"Pruthi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0800","series-title":"PTC Therapeutics initiates second phase 2 study of PTC124 in patients with cystic fibrosis in Israel","author":"PTC Therapeutics Inc.","year":"2005"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0795","series-title":"PTC Therapeutics initiates phase 2 study of PTC124 in cystic fibrosis","author":"PTC Therapeutics Inc.","year":"2005"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0805","series-title":"PTC Therapeutics announces positive phase 2 results for PTC124 in cystic fibrosis","author":"PTC Therapeutics Inc.","year":"2006"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0810","series-title":"PTC Therapeutics announces additional results from phase 2 study of PTC124 in Duchenne muscular dystrophy","author":"PTC Therapeutics Inc.","year":"2007"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0815","series-title":"PTC Therapeutics initiates phase 2 clinical trial of ataluren (PTC124\u00ae) in patients with hemophilia","author":"PTC Therapeutics Inc.","year":"2009"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0820","series-title":"Observational data from one-year follow-up study validate six-minute walk distance as an outcome measure in Duchenne and Becker muscular dystrophy","author":"PTC Therapeutics Inc.","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0825","series-title":"PTC Therapeutics completes enrollment of phase 3 trial of ataluren in patients with cystic fibrosis","author":"PTC Therapeutics Inc.","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0830","series-title":"PTC Therapeutics and Genzyme Corporation announce preliminary results from the phase 2B clinical trial of ataluren for nonsense mutation Duchenne\/Becker muscular dystrophy","author":"PTC Therapeutics Inc.","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0835","series-title":"Pivotal data presented at the world muscle society congress suggest ataluren slows the loss of walking ability in patients with nonsense mutation Duchenne\/Becker muscular dystrophy","author":"PTC Therapeutics Inc.","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0840","series-title":"PTC Therapeutics initiates phase 2 clinical trial of ataluren in patients with methylmalonic acidemia","author":"PTC Therapeutics Inc.","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0845","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0850","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00439-007-0410-7","article-title":"In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome","volume":"122","author":"Rebibo-Sabbah","year":"2007","journal-title":"Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0855","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/emboj\/18.11.3133","article-title":"Basis for prokaryotic specificity of action of aminoglycoside antibiotics","volume":"18","author":"Recht","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0860","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1261\/rna.2160905","article-title":"Nonsense-mediated mRNA decay factors act in concert to regulate common mRNA targets","volume":"11","author":"Rehwinkel","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0865","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tibs.2006.09.005","article-title":"Nonsense-mediated mRNA decay: Target genes and functional diversification of effectors","volume":"31","author":"Rehwinkel","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0870","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.canlet.2007.12.013","article-title":"Anti-proliferative effect of clitocine from the mushroom Leucopaxillus giganteus on human cervical cancer HeLa cells by inducing apoptosis","volume":"262","author":"Ren","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0875","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00125817-200209000-00010","article-title":"Standards and guidelines for CFTR mutation testing","volume":"4","author":"Richards","year":"2002","journal-title":"Genet Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0880","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s004390100473","article-title":"SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens","volume":"108","author":"Rochette","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0885","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: A consensus statement. Cystic Fibrosis Foundation Consensus Panel","volume":"132","author":"Rosenstein","year":"1998","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.007_bb0890","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0895","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/rcmb.2006-0176OC","article-title":"Restoration of W1282X CFTR activity by enhanced expression","volume":"37","author":"Rowe","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0900","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1128\/AAC.00455-07","article-title":"Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit","volume":"51","author":"Schroeder","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0905","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1210\/jc.2002-020286","article-title":"Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus","volume":"87","author":"Schulz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0910","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0915","first-page":"222","article-title":"Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease","volume":"50","author":"Shoshani","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0920","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1261\/rna.815108","article-title":"Proximity of the poly(A)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay","volume":"14","author":"Silva","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0925","doi-asserted-by":"crossref","first-page":"e13659","DOI":"10.1371\/journal.pone.0013659","article-title":"The effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients","volume":"5","author":"Simon","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0930","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1371\/journal.pbio.0060111","article-title":"A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay","volume":"6","author":"Singh","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0935","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0378-5955(96)00003-2","article-title":"Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo","volume":"94","author":"Song","year":"1996","journal-title":"Hear Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0940","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/gm13","article-title":"The Human Gene Mutation Database: 2008 update","volume":"1","author":"Stenson","year":"2009","journal-title":"Genome Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0945","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00239-004-0277-3","article-title":"Relationships among stop codon usage bias, its context, isochores, and gene expression level in various eukaryotes","volume":"61","author":"Sun","year":"2005","journal-title":"J Mol Evol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0950","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/MMBR.51.4.439-457.1987","article-title":"Bacterial uptake of aminoglycoside antibiotics","volume":"51","author":"Taber","year":"1987","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0955","series-title":"Aminoglycoside antibiotics: From chemical biology to drug discovery","first-page":"255","article-title":"Adverse effects of aminoglycoside therapy","author":"Talaska","year":"2007"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0960","series-title":"PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation","author":"Tan","year":"2011"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0965","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1139\/o95-118","article-title":"Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon","volume":"73","author":"Tate","year":"1995","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0970","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1128\/AAC.48.12.4889-4891.2004","article-title":"Effects of a number of classes of 50S inhibitors on stop codon readthrough during protein synthesis","volume":"48","author":"Thompson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0975","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/nar\/gkh201","article-title":"The major 5\u2032 determinant in stop codon read-through involves two adjacent adenines","volume":"32","author":"Tork","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0980","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7164\/antibiotics.29.937","article-title":"Structure-activity relationships among negamycin analogs","volume":"29","author":"Uehara","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0985","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7164\/antibiotics.25.685","article-title":"Negamycin, a miscoding antibiotic with a unique structure","volume":"25","author":"Uehara","year":"1972","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0990","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.molcel.2004.10.013","article-title":"SMG7 acts as a molecular link between mRNA surveillance and mRNA decay","volume":"16","author":"Unterholzner","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb0995","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1093\/nar\/23.22.4591","article-title":"Cysteine tRNAs of plant origin as novel UGA suppressors","volume":"23","author":"Urban","year":"1995","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1000","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/nar\/24.17.3424","article-title":"UGA suppression by tRNACmCATrp occurs in diverse virus RNAs due to a limited influence of the codon context","volume":"24","author":"Urban","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.20107","article-title":"Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease","volume":"55","author":"Usuki","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1357-2725(98)00134-4","article-title":"The role of the 5\u2032 untranslated region of an mRNA in translation regulation during development","volume":"31","author":"van der Velden","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1015","doi-asserted-by":"crossref","first-page":"e20733","DOI":"10.1371\/journal.pone.0020733","article-title":"Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations","volume":"6","author":"Vecsler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2011.10.005","article-title":"The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse","volume":"105","author":"Wang","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1030","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1021\/jm050368c","article-title":"Glycodiversification for the optimization of the kanamycin class aminoglycosides","volume":"48","author":"Wang","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/japplphysiol.01366.2009","article-title":"Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression","volume":"109","author":"Wang","year":"2010","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0b013e32833e1765","article-title":"The genetics of spinal muscular atrophies","volume":"23","author":"Wee","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1045","first-page":"A176","article-title":"Characterization of PTC124 activity, specificity, and mechanism of action for nonsense mutation suppression","volume":"64","author":"Welch","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1065","article-title":"Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease","volume":"Vol. 7247741B2","author":"Wilde","year":"2007"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1060","unstructured":"Wilde, R. G., Kennedy, P. D., Almstead, N. G., Welch, E. M., Takasugi, J. J., & Friesen, W. J. (2007). Nucleoside compounds and their use for treating cancer and diseaes associated with somatic mutations. In USPTO (Ed.), United States Patent (Vol. 7291603 B2). USA: PTC Therapeutics, Inc."},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1070","unstructured":"Wilde, R. G., Welch, E. M., Takasugi, J. J., Almstead, N. G., Rubenstein, S. M., & Beckmann, H. (2010). Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease In USPTO (Ed.), (Vol. 7763656B2). US: PTC Therapeutics, Inc. and Amgen Inc."},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1075","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/bi00600a002","article-title":"Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells","volume":"17","author":"Wilhelm","year":"1978","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/bi00600a001","article-title":"Aminoglycoside antibiotics and eukaryotic protein synthesis: structure\u2013function relationships in the stimulation of misreading with a wheat embryo system","volume":"17","author":"Wilhelm","year":"1978","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1085","first-page":"919","article-title":"Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides","volume":"237","author":"Williams","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1090","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1100","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/hmg\/ddi131","article-title":"A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels","volume":"14","author":"Wolstencroft","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1115","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/ja0318939","article-title":"Enhanced production of functional proteins from defective genes","volume":"126","author":"Xi","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1120","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.0610878104","article-title":"A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin","volume":"104","author":"Yang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hrthm.2009.01.017","article-title":"Aminoglycoside antibiotics restore functional expression of truncated HERG channels produced by nonsense mutations","volume":"6","author":"Yao","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1130","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/j.1460-2075.1992.tb05510.x","article-title":"The leaky UGA termination codon of tobacco rattle virus RNA is suppressed by tobacco chloroplast and cytoplasmic tRNAs(Trp) with CmCA anticodon","volume":"11","author":"Zerfass","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.2008.169805","article-title":"Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons","volume":"59","author":"Zilberberg","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2012.07.007_bb1150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/jhep.2002.30423","article-title":"Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells","volume":"35","author":"Zsembery","year":"2002","journal-title":"Hepatology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T04:44:27Z","timestamp":1714193067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":229,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0163725812001325"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717997797.793474350","asserted-by":"object"}]},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}